More perceived social support from classmates was tied to less disease severity in children with sickle cell anemia in ...

While both sickle cell trait and sickle cell disease involve mutations in the haemoglobin gene, they are fundamentally different in terms of symptoms, severity, and impact on daily life.

First Patient Dosed in the Phase 1/2 Study of BEAM-301 in Glycogen Storage Disease Type Ia, Beam’s Second Clinical Stage In ...

Martin Mwita, 20, is the first patient in St. Louis and among the first across the country to receive a new gene therapy for ...

The "Sickle Cell Disease Drugs Market - A Global and Regional Analysis: Focus on Route of Administration, Distribution Channel, and Country-Level Analysis - Analysis and Forecast, 2025-2035" report ...

Crispr Therapeutics is an emerging gene editing company focused on the development of Crispr/Cas9-based therapeutics. The company's proprietary platform specializes in clustered regularly interspaced ...

Enrollment complete in the 12 mg dose cohort (n=16) of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD); initiated the 20 mg dose cohort ― ― On track to provide clinical data from ...

Beam Therapeutics and Verve Therapeutics have each built their lead candidates on a technique billed as a safer alternative ...